Quest Enters Market For BRCA Gene Testing
This article was originally published in The Gray Sheet
Executive Summary
With the Oct. 15 launch of the BRCAvantage genetic test, Quest Diagnostics Inc. became the latest entrant into the now-competitive marketplace for BRCA diagnostic testing for the likelihood of inheriting breast or ovarian cancer.
You may also be interested in...
BRCA Reimbursement Cut Heightens Tensions Between CMS And Lab Industry
CMS has extended the comment period on its nearly 50 percent BRCA testing reimbursement cut to the end of February. But comments from lab and diagnostics groups so far try to underscore the “capriciousness and lack of transparency” that CMS displayed when it made the cut. Experts say the agency is unlikely to change its mind.
Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market
While the genetics firm is not wavering in its legal effort to protect its BRCA gene testing dominance, it is diversifying in response to inevitable competition, with a focus on a multigene panel and companion diagnostics.
News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.